# **Supporting Information**

## **Supplementary Table 1:** Search term for the literature search for *LRRK2* in PubMed

LRRK2	(ataxia OR ataxic OR cerebellar OR channelopathy OR dystonia OR dystonic OR parkinson*
	OR paroxysmal movement OR tremor OR myoclon* OR chorea OR choreo* OR choreatic
	OR spastic paraplegia OR spastic paraparesis OR HSP OR Strümpell* OR hyperkinetic OR
	"movement disorder" OR dyskinesia OR dyskinetic) AND (LRRK2 OR PARK8 OR DARDARIN
	OR RIPK7 OR ROCO2 OR AURA17 OR DKFZp434H2111 OR FLJ45829 OR RIPK7 OR "Leucin-
	rich repeat kinase 2" OR 12q12) AND ("english"[Language])

**Supplementary Table 2:** List of variables. Demographic, clinical, and genetic information extracted using the MDSGene protocol.

#### **Patient characterization**

individual patient ID

family ID

#### **Demographic information**

ethnicity

country of origin

sex

#### **Genetic information**

genetic status of all tested family members with number of homozygous, heterozygous and wildtype ones in affected and unaffected state

human genome version number

genome build or accession ID

gene to which the variant refers

physical location of the variant (on the plus strand)

observed mutated bases (on the plus strand)

reference bases (on the plus strand)

genomic description of the variant according to the nomenclature of the human genome variation society (HGVS)

coding description of the variant according to the nomenclature of the HGVS

protein description of the variant according to the nomenclature of the HGVS

genotype of the respective variant

type of variant

highest minor allele frequency (MAF) of the respective variant found in gnomAD

pathogenicity status classified as likely benign, benign, VUS (variant of unknown significance), likely pathogenic or pathogenic

CADD score as one parameter for pathogenicity scoring

Functional evidence

### **Clinical information**

general

positive family history for the variant associated phenotype

age at examination in years

age at disease onset in years

disease duration in years

age at clinical diagnosis in years

age at death

presence of parkinsonian syndrome

motor instrument like UPDRS III or Hoehn&Yahr and, if available, their scoring

presence of non-motor signs and symptoms associated with a parkinsonian syndrome

non-motor symptoms instrument

presence of atypical signs and symptoms for a parkinsonian syndrome

reported initial signs and symptoms

motor signs and symptoms

bradykinesia

tremor (in general: HP:0001337)

rest tremor

action tremor

postural tremor

dystonic tremor

rigidity

postural instability

levodopa responsiveness

levodopa response quantification classified as minimal/intermittent, moderate, or good/excellent

dyskinesia

dystonia
hyperreflexia
diurnal fluctuations as motor symptom fluctuations throughout the day
sleep benefit as restoration of mobility upon awakening from sleep
motor fluctuations in context of medication-intake
non-motor signs and symptoms
hyposmia
depression
depression scale
anxiety
anxiety scale
psychotic symptoms
psychosis scale
sleep disorder
cognitive decline
autonomic symptoms

## **Supplementary Table 3:** Documented *LRRK2* variants in all extracted variant carriers.

## A: Variants classified as pathogenic, likely pathogenic, likely benign, or benign

Pathogenic	Likely Pathogenic	Likely Benign	Benign
R1325Q	R767H	H115P	IVS2+1366C>G
N1437H	R1067Q	L119P	IVS5+33T>C
R1441C	N1437D	IVS4-38A>G	N551K
R1441G	N1437S	M262V	1723V
R1441H	F1700L	P755L	IVS19-10dupT
R1441S	S1761R	S865F	Q1111H
A1442P	S1954F <sup>1</sup>	C925Y	P1262A
V1447M	12020L	L1281L	R1398H
Y1699C	12020S	I1371V	T1410M
F1700L	T2031S	R1441R	K1423K
L1795F <sup>2</sup>		Y1527Y	IVS30+12delT
G2019S		Y2018Y	R1514Q
12020T		H2391Q	M1646T
			S1647T
			N2081D
			G2385G

<sup>&</sup>lt;sup>1</sup>This variant was only found in a patient with breast cancer and not included in MDSGene

<sup>&</sup>lt;sup>2</sup> This variant is encoded by two different substitutions on the cDNA level (c.5385G>C and c.5385G>T)

## B: Variants classified as VUS

E10K	K544E	S1007T	S1445F	Y1649S	E2230K
K53R	M579V	H1019R	P1446L	P1661T	H2236R
M100T	I610T	Q1029H	V1450I	R1677S	N2251T
Q116R	K616R	N1089S	G1451S	I1691T	N2261K
S128G	S633F	S1096C	A1464G	R1693Q	G2294R
L153W	T646A	L1114L	K1468E	S1706*	N2308D
N173S	A654V	I1122V	P1480L	R1707K	T2310M
S192A	S661F	L1128M	A1481T	L1712F	N2313S
E193A	I675M	A1151T	R1483Q	R1725Q	I2323F
E193K	F676S	C1152F	A1490V	S1752C	I2336V
A211V	S722N	S1159R	T1491del	D1756G	S2350I
C228S	M724V	L1165P	E1492K	D1756Y	T2356I
H230R	D734N	S1181Y	R1501W	H1758P	G2385R#
N238I	K739R	I1192M	I1505Rfs*16	R1771T	V2390A
Y250C	S764N	I1192V	S1508G	K1772del	V2390M
E255K	R767C	A1215T	G1520A	C1774Y	E2395K
K258N	R772*	H1216R	V1541M	T1806I	M2408I
A259E	T776M	S1228T	I1548V	G1819R	T2423S
L286V	1777M	T1271I	R1552*	Q1823K	I2434V
V291A	S784R	W1295R	A1589S	M1869T	L2439I
A306V	1786F	L1304F	V1613A	M1869V	A2461V
L308M	R792K	R1334Q	V1615M	E1874*	L2463P
A312V	R793M	I1339M	V1615V	D1887N	Q2490H
T320S	S827F	V1340M	E1616K	G1891A	T2494I
S231P	1844N	Q1353K	P1619L	L1914I	V2495I
E334K#	M848T	V1369A	K1620R	R1941H	T2524A
N335S	S858*	V1373M	H1621R	Q1961R	IVS4-68T>C
A370T	S885C	Q1379R	H1621Q	I1991V	IVS8+1G>A
L378F	E899D	L1388I	P1622L	Y2006H	IVS19+5delGTA
M379I	L922*	V1389I	P1622P	A2010T	IVS30+1G>C
1388T	Q923H	R1398C	P1622T	I2012T	IVS31+3A>G
V414I	Q930R	R1398R	K1623E	L2063*	IVS33+6T>A
A419V	D941Y	Y1402C	I1626V	V2074I	IVS33+78T>C
L425P	D944V	H1405Q	S1627L	E2108K	IVS33+70T>C
L437S	R948Q	A1413T	S1627T	N2133S	IVS33+79T>C
S438P	S958L	R1320S	R1628C	C2139S	IVS36-29G>T
A459S	D972G	E1427G	R1628P#	V2150I	IVS40-28A>T
S461I	S973G	F1436L	R1639Kfs*13	W2168L	IVS49+178A>G
N474S	S973N	A1440P	Y1645S	D2175H	Exon 49 deletio
R521G	R981K	S1445C	Q1648R	Y2189C	
K535Nfs*13					

<sup>#:</sup> established risk variants

# **Supplementary Table 4:** Numbers and frequencies of pathogenic or likely pathogenic *LRRK2* variants in affected PD patients and unaffected individuals.

Variant	Number of affected	patients (frequency)	Number of unaffected carriers
Pathogenic variar	nts	<u>.</u>	
G2019S	2426	(73.60%)	739
R1441G	193	(5.86%)	90
R1441C	96	(2.91%)	17
12020T	43	(1.30%)	5
R1441H	39	(1.18%)	4
Y1699C	32	(0.97%)	0
N1437H	9	(0.27%)	1
V1447M	6	(0.18%)	0
L1795F	4	(0.12%)	0
R1441S	4	(0.12%)	0
R1325Q	3	(0.09%)	6
F1700L	2	(0.06%)	0
A1442P	1	(0.03%)	0
Likely pathogenic	variants		
R1067Q	9	(0.27%)	0
N1437D	7	(0.21%)	0
S1761R	7	(0.21%)	0
N1437S	5	(0.15%)	0
12020L	1	(0.03%)	0
12020S	1	(0.03%)	0
R767H	1	(0.03%)	0
T2031S	1	(0.03%)	0
S1954F*	0	(0.00%)	0

<sup>\*</sup> found in 1 patient with breast cancer

**Supplementary Table 5:** Age at onset (AAO) of PD in all included patients, in the included patients with VUS and in the included patients with (likely) pathogenic variants. First number indicates the number of patients, number in parentheses is the respective frequency.

Age at onset	Patients with VUS		Patients with VUS  Patients with (likely) pathogenic variants		All patients	
0-9	0	(0.0%)	0	(0.0%)	0	(0.0%)
10-19	0	(0.0%)	0	(0.0%)	0	(0.0%)
20-29	4	(2.8%)	11	(1.3%)	15	(1.5%)
30-39	15	(10.6%)	63	(7.3%)	78	(7.8%)
40-49	44	(31.0%)	191	(22.1%)	235	(23.4%)
50-59	23	(16.2%)	257	(29.8%)	280	(27.9%)
60-69	33	(23.2%)	217	(25.1%)	250	(24.9%)
70-79	23	(16.2%)	108	(12.5%)	131	(13.0%)
80-89	0	(0.0%)	15	(1.7%)	15	(1.5%)
90-99	0	(0.0%)	1	(0.1%)	1	(0.1%)
known	142	(100.0%)	863	(100.0%)	1005	(100.0%)
unknown	260		2031		2291	
total	402		2894		3296	

**Supplementary Table 6**: Information on reported signs and symptoms in all included patients. First number indicates the number of patients, number in parentheses is the respective frequency.

Symptoms	Present		Absent		Unknown	
Motor symptoms	3296	(100%)	0	(0.0%)	0	(0.0%)
Parkinsonism	3296	(100%)	0	(0.0%)	0	(0.0%)
Bradykinesia	2452	(74.4%)	10	(0.3%)	834	(25.3%)
Rigidity	692	(21.0%)	10	(0.3%)	2594	(78.7%)
Tremor (any or unspecified)	636	(19.3%)	70	(2.1%)	2590	(78.6%)
Resting tremor	409	(12.4%)	75	(2.3%)	2812	(85.3%)
Action tremor	20	(0.6%)	7	(0.2%)	3269	(99.2%)
Postural tremor	24	(0.7%)	10	(0.3%)	3262	(99.0%)
Dystonic tremor	0	(0.0%)	3	(0.1%)	3293	(99.9%)
Postural instability	258	(7.8%)	104	(3.2%)	2934	(89.0%)
Dyskinesia	213	(6.5%)	103	(3.1%)	2980	(90.4%)
Dystonia	70	(2.1%)	111	(3.4%)	3115	(94.5%)
Hyperreflexia	12	(0.4%)	49	(1.5%)	3235	(98.1%)
Diurnal fluctuations	2	(0.1%)	0	(0.0%)	3294	(99.9%)
Sleep benefit	17	(0.5%)	59	(1.8%)	3220	(97.7%)
Motor fluctutations	146	(4.4%)	68	(2.1%)	3082	(93.5%)
Non-motor symptoms	311	(9.4%)	28	(0.8%)	2957	(89.7%)
Hyposmia	46	(1.4%)	11	(0.3%)	3239	(98.3%)
Depression	114	(3.5%)	160	(4.9%)	3022	(91.7%)
Anxiety	49	(1.5%)	110	(3.3%)	3137	(95.2%)
Psychotic symptoms	67	(2.0%)	141	(4.3%)	3088	(93.7%)
Sleep disorder	72	(2.2%)	55	(1.7%)	3169	(96.1%)
Cognitive decline	120	(3.6%)	331	(10.0%)	2845	(86.3%)
Autonomic symptoms	63	(1.9%)	79	(2.4%)	3154	(95.7%)
Atypical parkinsonism symptoms	10	(0.3%)	311	(9.4%)	2975	(90.3%)

**Supplementary Table 7:** Information on reported signs and symptoms in the patients with (likely) pathogenic variants (n=2,894). First number indicates the number of patients, number in parentheses is the respective frequency.

Symptoms	Pr	Present		Absent		Unknown	
Motor symptoms	2894	(100.0%)	0	(0.0%)	0	(0.0%)	
Parkinsonism	2894	(100.0%)	0	(0.0%)	0	(0.0%)	
Bradykinesia	2176	(75.2%)	8	(0.3%)	710	(24.5%)	
Rigidity	621	(21.5%)	7	(0.2%)	2266	(78.3%)	
Tremor (any or unspecified)	556	(19.2%)	63	(2.2%)	2275	(78.6%)	
Resting tremor	352	(12.2%)	60	(2.1%)	2482	(85.8%)	
Action tremor	17	(0.6%)	7	(0.2%)	2870	(99.2%)	
Postural tremor	18	(0.6%)	9	(0.3%)	2867	(99.1%)	
Dystonic tremor	0	(0.0%)	3	(0.1%)	2891	(99.9%)	
Postural instability	230	(7.9%)	83	(2.9%)	2581	(89.2%)	
Dyskinesia	201	(6.9%)	88	(3.0%)	2605	(90.0%)	
Dystonia	65	(2.2%)	96	(3.3%)	2733	(94.4%)	
Hyperreflexia	12	(0.4%)	46	(1.6%)	2836	(98.0%)	
Diurnal fluctuations	2	(0.1%)	0	(0.0%)	2892	(99.9%)	
Sleep benefit	15	(0.5%)	59	(2.0%)	2820	(97.4%)	
Motor fluctutations	135	(4.7%)	65	(2.2%)	2694	(93.1%)	
Non-motor symptoms	265	(9.2%)	28	(1.0%)	2601	(89.9%)	
Hyposmia	37	(1.3%)	7	(0.2%)	2850	(98.5%)	
Depression	104	(3.6%)	150	(5.2%)	2640	(91.2%)	
Anxiety	47	(1.6%)	110	(3.8%)	2737	(94.6%)	
Psychotic symptoms	63	(2.2%)	133	(4.6%)	2698	(93.2%)	
Sleep disorder	60	(2.1%)	48	(1.7%)	2786	(96.3%)	
Cognitive decline	105	(3.6%)	311	(10.7%)	2478	(85.6%)	
Autonomic symptoms	51	(1.8%)	74	(2.6%)	2769	(95.7%)	
Atypical parkinsonism symptoms	8	(0.3%)	305	(10.5%)	2581	(89.2%)	

**Supplementary Table 8:** Information on reported signs and symptoms in the patients with VUS (n=402). First number indicates the number of patients, number in parentheses is the respective frequency.


Symptoms	Pre	Present		Absent		Unknown	
Motor symptoms	402	(100.0%)	0	(0.0%)	0	(0.0%)	
Parkinsonism	402	(100.0%)	0	(0.0%)	0	(0.0%)	
Bradykinesia	276	(68.7%)	2	(0.5%)	124	(30.8%)	
Rigidity	71	(17.7%)	3	(0.7%)	328	(81.6%)	
Tremor (any or unspecified)	80	(19.9%)	7	(1.7%)	315	(78.4%)	
Resting tremor	57	(14.2%)	15	(3.7%)	330	(82.1%)	
Action tremor	3	(0.7%)	0	(0.0%)	399	(99.3%)	
Postural tremor	6	(1.5%)	1	(0.2%)	395	(98.3%)	
Dystonic tremor	0	(0.0%)	0	(0.0%)	402	(100.0%)	
Postural instability	28	(7.0%)	21	(5.2%)	353	(87.8%)	
Dyskinesia	12	(3.0%)	15	(3.7%)	375	(93.3%)	
Dystonia	5	(1.2%)	15	(3.7%)	382	(95.0%)	
Hyperreflexia	0	(0.0%)	3	(0.7%)	399	(99.3%)	
Diurnal fluctuations	0	(0.0%)	0	(0.0%)	402	(100.0%)	
Sleep benefit	2	(0.5%)	0	(0.0%)	400	(99.5%)	
Motor fluctutations	10	(2.5%)	3	(0.7%)	389	(96.8%)	
Non-motor symptoms	43	(10.7%)	0	(0.0%)	359	(89.3%)	
Hyposmia	9	(2.2%)	4	(1.0%)	389	(96.8%)	
Depression	10	(2.5%)	10	(2.5%)	382	(95.0%)	
Anxiety	2	(0.5%)	0	(0.0%)	400	(99.5%)	
Psychotic symptoms	4	(1.0%)	8	(2.0%)	390	(97.0%)	
Sleep disorder	12	(3.0%)	7	(1.7%)	383	(95.3%)	
Cognitive decline	15	(3.7%)	19	(4.7%)	368	(91.5%)	
Autonomic symptoms	12	(3.0%)	5	(1.2%)	385	(95.8%)	
Atypical parkinsonism symptoms	2	(0.5%)	6	(1.5%)	394	(98.0%)	

**Supplementary Table 9:** Reported initial signs and symptoms in the included patients with VUS, in patients with (likely) pathogenic variants, and in all included patients. First number indicates the number of patients, numbers in parentheses are the respective frequencies among all patients in the same group (middle panel) and patients in the same group with information (right panel).


Initial symptoms	P	atients wit	h VUS		Patients with (likely) pathogenic variants			All included patients	
Tremor (any or unspecified)	19	(4.8%)	(43.2%)	240	(8.3%)	(53.7%)	259	(7.9%)	(52.7%)
Bradykinesia	16	(4.0%)	(36.4%)	168	(5.8%)	(37.6%)	184	(5.6%)	(37.5%)
Rigidity	5	(1.2%)	(11.4%)	73	(2.5%)	(16.3%)	78	(2.4%)	(15.9%)
Resting tremor	11	(2.7%)	(25.0%)	58	(2.0%)	(13.0%)	69	(2.1%)	(14.1%)
Postural instability	1	(0.2%)	(2.3%)	5	(0.2%)	(1.1%)	6	(0.2%)	(1.2%)
Dystonia	0	(0.0%)	(0.0%)	7	(0.2%)	(1.6%)	7	(0.2%)	(1.4%)
Anxiety	0	(0.0%)	(0.0%)	3	(0.1%)	(0.7%)	3	(0.1%)	(0.6%)
Cognitive decline	1	(0.2%)	(2.3%)	2	(0.1%)	(0.4%)	3	(0.1%)	(0.6%)
Sleep disorder	0	(0.0%)	(0.0%)	1	(0.0%)	(0.2%)	1	(0.0%)	(0.2%)
Depression	0	(0.0%)	(0.0%)	7	(0.2%)	(1.6%)	7	(0.2%)	(1.4%)
Tremor postural	0	(0.0%)	(0.0%)	1	(0.0%)	(0.2%)	1	(0.0%)	(0.2%)
Psychotic symptoms	0	(0.0%)	(0.0%)	1	(0.0%)	(0.2%)	1	(0.0%)	(0.2%)
Known	44	(10.9%)	(100.0%)	447	(15.4%)	(100.0%)	491	(14.9%)	(100.0%)
Unknown	358	(89.1%)		2447	(84.6%)		2805	(85.1%)	
All	402	(100.0%)		2894	(100.0%)		3296	(100.0%)	

**Supplementary Table 10:** Levodopa response quantifications in the included PD patients with VUS, in the included PD patients with (likely) pathogenic *LRRK2* variants, and in all included PD patients.


Levodopa response	Patients with VUS			Patients with (likely) pathogenic variants		All included patients	
good/excellent	53	(13.2%)	341	(11.8%)	394	(12.0%)	
moderate	0	(0.0%)	5	(0.2%)	5	(0.2%)	
minimal/intermittent	2	(0.5%)	8	(0.3%)	10	(0.3%)	
yes, undefined	34	(8.5%)	404	(14.0%)	438	(13.3%)	
no	1	(0.2%)	2	(0.1%)	3	(0.1%)	
not treated	5	(1.2%)	18	(0.6%)	23	(0.7%)	
unknown	307	(76.4%)	2116	(73.1%)	2423	(73.5%)	
total	402	(100.0%)	2894	(100.0%)	3296	(100.0%)	




В




**Supplementary Figure 1:** Origin of included PD patients. **A)** Ethnicities of the included patients with the most frequent variant per ethnicity highlighted. **B)** World map for included PD patients with LRRK2 variants. The country of origin with the highest number of affected LRRK2 carriers is Tunisia (n = 553, followed by Spain (n = 313) and Italy (n = 135).



**Supplementary Figure 2:** Percentages of features reported to be present among all patients in the respective group. All reported signs and symptoms ("present") in the included patients with VUS (n=402), with (likely) pathogenic variants (n=2,894), and in all included PD patients (n=3,296). Of note, there is bias in this presentation since the diagram includes only information from patients with available data and there might be overreporting of unusual features combined with underreporting of the absence of respective features (missing data) leading to a too-high frequency, especially when the sample size (patients with information) is small.



**Supplementary Figure 3:** Initial signs and symptoms ("present") in all included patients with information (blue, n=491), in the included patients with VUS (gray, n=44) and with (likely) pathogenic variants (red, n=447).



**Supplementary Figure 4:** Levodopa response quantifications in all included PD patients with information (blue, n=873), in the included PD patients with VUS (gray, n=95) and in the included PD patients with (likely) pathogenic *LRRK2* variants (red, n=778).